<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Choice of anticoagulant in patients with STEMI by reperfusion strategy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Choice of anticoagulant in patients with STEMI by reperfusion strategy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Choice of anticoagulant in patients with STEMI by reperfusion strategy</div><div class="cntnt"><img src="data:png;base64,iVBORw0KGgoAAAANSUhEUgAAAfUAAADvBAMAAAAZXFBrAAAACXBIWXMAAAPoAAAD6AG1e1JrAAAAJFBMVEX///8AAABGRkaIiIgoKCi7u7vk5OScnJxmZmYQEBDNzc14eHiCNSjdAAAL+klEQVR42uydy1PbWBaHryRLMnjjY0uWoTcyZghV2chqk57spDgxhNlY1aSr0ysZk1Q7KzvQPcWsTKaToXoFYQLpzMZ09/RUajYwlamaP2/uvTJv8zDIjQznt7HR4+h8OvdlcXQvISgUCoVCoVAoVEfwuysZGfbkLbgisiM7siM7siM7siM7st8Odv34DtG6sA0xddEjnYixK6PqqLoWsOcJkZMB+RF2yTzLxrJ/4qDO2Yc2xWGWlGZaEYt7KbGRMPfZ93zvIe52l6JgnbxnYySejlqZ/0/MjlkaNFbgz2DQuC+DRZrw0s0qbpYQwTVEu2SOw/iI72pt44EuZ4isGwWtTc+Zg4bxAAxddXbhF/PpSGMcWkTJjdDz7WnIVuENMwNfm+IOWSWl91GL+8d6vdpOSw6JO7zM3w3ibnrzrXqbCNZ9sSyZY6oes0hsJ0VW4y0ip4c/JMy0tLalrqWIrVB2gwZ5Q90cY3cmw84vE9KsmWKr/rMjfJWp+j+Xo1ffyZAdKxLq/X0I2OdSbV7mqwsADSJUvHlLMvNyUry3Ai2dPK369CAVwKElACCjB+zFbG0iQzJ5JUPI7gY7X3WhZsYAlhpCJf8/shTFdl7cSPyDspeNhHOXt3Vii4g7lH2ellDK/knssH+RiVF28QE7aPgD7RsSzhbrIWxiiA4ZWjQ3pE3OTrbn6fmxnWbNYbbM7crch2j2cdKoarC45zSnyep7TmsTFV5a1ecu+ESAR3vs91yNsqs6v0EFaIFWmaPRp+wFrbyu1Vh9Z+wyZNn5Ergv1t+48MJ1KzEzmnE/W0Ll2IaDtlu/6EW2/XplEMd1J9jrjR7ZZUiTTzimRXZkR3ZkR3ZkR3ZkR3ZkR/YwdZvzLm5A+JAd2ZEd2ZEd2ZH91rDDQCoZ9eBE3jSyIzuyIzuyI/utMo1CoVAo1GmSD/c/Z2dXX02efpWzRUiTAkxAJix3RADvCWfPH2HvIeO6m3JWtXJyayn4ECqXc7Xl/XtW+cMlz+5qsC9xH890Y393RVeHlhuXvnPd2YUnmtY2ZvKCa8jrW9KELmdyI+K93MgVzE6OVSu5lE9Eu+xmpcean9Oe6QAzZuwvbkpguzRo9Oxqs+qHyg4p4cmoaKZIXrCKQ9ZyzVyNv84QcepK1WrSK3xZXrCIWBZb9V/KC5+XY1NposfN2KJDBLaL5bf36qoxFH7ck5KjU/bKUtUXaubTqs/yxXc3rsIuwtctqUWbjRjAoimuArxOcvbvc9MC26WrTu+uJh6FXN8pO0sjZ+xD1v2ayfLJt+ctsu1fgV2BIO4WvYBk1hfLrFXRJedpgxR53C/FTlbgTYjtPGMHzQ/YWX03VV2GrDgF2avEnawE9d1SXKhBiuTgO8quuI8XweD1vXf230Oh9/D9HDKErHrj9rKjUCgUCnVdSt5i08iO7Mh+W9hfkOSw3x/3Im+6esfI9cnByJuOw5UeKgy06WGA0T45GH3TOejbo4DIm272/GD75pgeGumXf9E3nfisbw5G3rSS6ZuD0Tdd6d/gazBN3xxdMU39mrLjw0muv/zAP9nnnyT9uSyyIzuyI3sYTiiudfDHkZkogyyGnrKq5OQAsbt+wvQOyE9n30vnyB89Pz+47PLfLdG6EPvNi3v8jtME0EQoe15DgWzRpV8WYVZ0U+6m4BoS/frFpjTrpoRvXD4jb34e1ogC2jNtpF0AM0+PkCAlsklKpcds6782j2VJRZW9/v07FveiX/IsFvfi8y3P2m6/Es1mpSRY99lXazpI/gqI8p7PPqrf6eKPhmTm6RHbDTuYpLS8MKWLrelYIzLsu2CSWKa7E03IMvYVyHqdMj/tkSUyxzbmhYrHv9pLSm5a+Co3zdkTIxYZZulB8b85lJ0esUTsziSl4utkvGUvhVTmd/nznPPZD9qcg/oZ1ONh0E3ytNTdibvEm7c8v+jzg4sB+3Z7rMP+iX+t05OLtPIXpU12oeEMiTtVyv7jqMjiPsYPYpOUmnW6tVUvhcPOHT/BnifVZwB5h5QOs9t77HsZyR5P5OEmVotdnVBGScy2Fmh9Nxj7xyxnZ5Wcs8Mj/jWxKYEhfAkGu615D1pEXncZ5YrG63scHohsktIapGS6NbF5CrtH4i0APUNenYd94HhX9gyRjrGfEndS0E1FrzYuH4B9i3X/+J5W8Dl54PHJjuEIu8EmMX51sesWzmNfgB274JNxaNnVtvctC47uec3KkuyCZLLZooluSk7cvDx70z9lR07je2gvcZj9+OFd2UWYoD0L9b5FuxZadrzGTAxmac8Sh8502Nzx08r8lwBpQsaG3xUr7GPUFlv0/v/A2K0qywGlZZ7NFk1NxCz2ed1j2qDMTwHQzrL4nPcsk8oH2rXQvkJ9Szn/RHsWRlDed7wb+/Z+3KfJHZuXecOWNzPSusbYSZXl/lJ2PmOybnr8NvWb/ZQ8wUPs4s5e3FfJH1mVdMGgTQztK8iK/y1kac9SYwT7jp9k/+T/IO+xjw3rnF3N2OShWW184uxCY3zIKhw2cZEGN98Tqt0Zxe2P5YqTZ7NXrY+NPXYW96ChoOy0o1AfmE1/hvYsnOAM9nmYlQ/Xd1b1wLJJsyLCQ84uwUMV3F7Y5aR9KjsPaLBTBs3/FUqFLHVaeHLAvqK11XL34e/+ZdX1z8jh+k6Y9zRk06y+/zazADNsLmxGcAZ7f35M2mfHvcOeESfeE5vdjaNxF81qRTGu+Bu2W/57n9ljFhH/m4Esb1xXgK0lUFwPBvadVQj4EgVz0KDsUskJSgKL+69WTnuWLClbtBk7N+6RZE+Yk0P/pGWeN6500EY7Dd4O0/a3swoBX6JgS12j7At/be2zjz6SyrGp5JLqDI/759b3SD63UbeKy7y+s0rGVyOgre8kH9h3ViFgGxUANtW8VjuI+8hOnL3wUZ9rsGx/qTWIz6x+qr2Vk0XOrhgJh3UayhYf2AerEEzwJQq2eH0nyttOfRee6BsSe+FDejzAz+vGFENOfszyuOc0h3Ya9Kc5H9h3ViHIsSUK5sBh7GTuoJ3/2GK/6JQ0OeMtj8F6Vnnww+hib13JmzfnOW2v7LEdfEaN7MiO7MiO7CGw3+a8i+tSFHxAdmRHdmRHdmRHdmQ/S0KfhnIDwT5QZpEd2ZEd2ZEd2ZEdhUKhUKjbqnpDNPthV0qRUtTZpfKy3xe7PzUiz04mSySnvQjeAAqTvbRZkmA22uxVUyrHPnfCL0/vS9vtV9FmF604wJvgDaAw2Z1CmiWFR5xdYu87FENnj6W322NRZycrsAhG6OxqOvL1HYVCoVAoFOqGCf83gezIjuw3n11pC+S3gTEbspOp5svMwJgNWSvAXnweFLPhahugPThmw5UIqQEyG67U0B/W9dNsyFpfGySz4Wp3Z5DMhiu2rujgmA1X8kCZRZ03nu5PRrwwCIn2Qn8sCgPgKLIjO7IjO7IjO7Ij+y1m373AMl4hs9NLDrva9bN3pj4OkV3aH6brp1+STRZ8Tex58v/2zqclgSAM47N/XCNPo7O71WnTPsASe+nm4rKKXVzo4m1NEexkpNFxEyHoFoF71egDlPgBm3cMkRBSCbbyfT7APPx4ZmAGhudtNCk9jTR9I3aV0nD1csvP99oq9qUyS7BMeY9JsheJzNk/a5/XZO+uYT8h3+QOlnvRe5g8O9mMXfFYeJxtjjq3MHyAjV02NisFyTVF6azUi4h7UD+ErtMW1RvUD9wqNE33Bjaj3QEpn7VjsJT9izDRPS9TuiE7pU2/c+O37FkJhg8cyRZR37KkINmOKBuWLOhefk6P8ikjz3PXzAD+l55LlmznlCJnz3i2sJzmktvzk21zt9S7SInUohg+oPj3NNKhp78nSqah5zDQDGIUNKNM9BcotndE07Rs62lgJx6ZW14nxT4Lh8rW7JD7tCSGD6gPhrpgh9xrIndlxNnz+/qQ504qomlasDupOHMicldonBT7Ja1uxc73vKV2+Xn3J/0nt09Z22ULdjjvgp2fd87+yvQ6MwPqQ9P0nL3FYufKXFj+5XvdqnEyXxX80zvtLrPjWwbZkR3ZkR3ZkR3ZkR3Zkf3nl9zhfxcoFAqFQqFQqF+tD8OdtbEApcaIAAAAAElFTkSuQmCC"/></div><div class="graphic_footnotes"><p>STEMI: ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; UFH: unfractionated heparin; eGFR: estimated glomerular filtration rate.</p>
<p>* For further information on choosing a reperfusion strategy, refer to UpToDate content on reperfusion in STEMI.</p>
<p>¶ In patients with prior history of heparin-induced thrombocytopenia, bivalirudin is the anticoagulant of choice.</p>
<p>Δ For additional details on the differences between UFH and bivalirudin, refer to UpToDate content on anticoagulation in patients with STEMI. In patients treated with bivalirudin, the infusion should continue after PCI at 1.75 mg/kg/h (1.0 mg/kg/h for eGFR &lt;30 mL/1.73 m<sup>2</sup>) for 2 to 4 hours.</p>
<p>◊ Refer to UpToDate content on selecting a reperfusion strategy for more information on the approach to PCI after primary fibrinolysis.</p>
§ Fondaparinux may not be available for use in some regions (eg, United States).</div><div id="graphicVersion">Graphic 139386 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
